Vanguard Personalized Indexing Management LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD

Vanguard Personalized Indexing Management LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 199,160 shares of the biopharmaceutical company’s stock after buying an additional 5,132 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Gilead Sciences were worth $22,116,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth approximately $26,000. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences in the second quarter valued at approximately $27,000. Putney Financial Group LLC increased its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute purchased a new stake in shares of Gilead Sciences during the second quarter valued at approximately $30,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on GILD. TD Cowen boosted their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Rothschild & Co Redburn lifted their target price on Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Scotiabank began coverage on shares of Gilead Sciences in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 price objective on shares of Gilead Sciences in a research report on Friday, October 31st. Finally, Mizuho raised their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.52.

Insider Activity

In other news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the sale, the director directly owned 1,339 shares in the company, valued at $170,186.90. This represents a 67.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $124.83, for a total transaction of $1,248,300.00. Following the completion of the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at $70,740,911.34. This trade represents a 1.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 141,757 shares of company stock valued at $17,569,112. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 3.7%

Gilead Sciences stock opened at $135.93 on Monday. The firm has a 50 day simple moving average of $123.98 and a 200 day simple moving average of $118.71. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 1-year low of $92.26 and a 1-year high of $136.30. The firm has a market capitalization of $168.65 billion, a price-to-earnings ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.